SG11201901081XA - Process for the preparation of highly concentrated liquid formulations containing biomolecules - Google Patents

Process for the preparation of highly concentrated liquid formulations containing biomolecules

Info

Publication number
SG11201901081XA
SG11201901081XA SG11201901081XA SG11201901081XA SG11201901081XA SG 11201901081X A SG11201901081X A SG 11201901081XA SG 11201901081X A SG11201901081X A SG 11201901081XA SG 11201901081X A SG11201901081X A SG 11201901081XA SG 11201901081X A SG11201901081X A SG 11201901081XA
Authority
SG
Singapore
Prior art keywords
international
rhein
binger
ingelheim
preparation
Prior art date
Application number
SG11201901081XA
Other languages
English (en)
Inventor
Patrick Garidel
Sven Bahrenburg
Torsten Schultz-Fademrecht
Andrea Eiperle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG11201901081XA publication Critical patent/SG11201901081XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201901081XA 2016-08-17 2017-08-11 Process for the preparation of highly concentrated liquid formulations containing biomolecules SG11201901081XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16184502 2016-08-17
PCT/EP2017/070423 WO2018033482A1 (en) 2016-08-17 2017-08-11 Process for the preparation of highly concentrated liquid formulations containing biomolecules

Publications (1)

Publication Number Publication Date
SG11201901081XA true SG11201901081XA (en) 2019-03-28

Family

ID=56740111

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901081XA SG11201901081XA (en) 2016-08-17 2017-08-11 Process for the preparation of highly concentrated liquid formulations containing biomolecules

Country Status (9)

Country Link
US (1) US11572385B2 (de)
EP (1) EP3500588A1 (de)
JP (3) JP7114567B2 (de)
KR (1) KR102457855B1 (de)
CN (2) CN118085011A (de)
AU (2) AU2017313268B2 (de)
CA (1) CA3031860A1 (de)
SG (1) SG11201901081XA (de)
WO (1) WO2018033482A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7162072B2 (ja) * 2018-03-26 2022-10-27 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 免疫原性組成物を製造する方法
AU2019250882A1 (en) * 2018-04-12 2020-11-05 Amgen Inc. Methods for making stable protein compositions
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
CN111096456A (zh) * 2020-02-14 2020-05-05 江西师范大学 一种荷叶中抑制晚期糖基化产物形成活性组分的制备方法
CA3229424A1 (en) 2021-09-02 2023-03-09 Boehringer Ingelheim International Gmbh Method of determining a future color value or corresponding property and arrangement therefor
WO2024008256A1 (en) * 2022-07-05 2024-01-11 Lihme Protein Solutions Improved apparatus for compound separation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199058A (en) * 1980-12-05 1985-04-30 Schreiber Foods Inc Producing cheese or a cheese base containing casein and whey proteins
SE500110C2 (sv) 1989-06-27 1994-04-18 Kabi Pharmacia Ab Sätt att rena ett protein från därtill bundna flervärda metalljoner
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5564414A (en) 1994-05-26 1996-10-15 Walker; William F. Pressurized and metered medication dose counter on removable sleeve
US6312755B1 (en) * 1999-07-16 2001-11-06 Ampc Whey treatment process for achieving high concentration of α-lactalbumin
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US6712963B2 (en) * 2002-06-14 2004-03-30 Scilog, Llc Single-use manifold for automated, aseptic transfer of solutions in bioprocessing applications
US7241874B2 (en) * 2002-06-26 2007-07-10 Zimmer Ortho Biologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
EP1386630B1 (de) 2002-07-31 2006-05-17 CHIESI FARMACEUTICI S.p.A. Pulverinhalator
EP1596667B1 (de) 2002-11-01 2009-01-21 Bayer HealthCare LLC Verfahren zur Konzentration von Proteinen
CA2554883C (en) 2004-01-30 2013-10-01 Zymenex A/S Production and purification of recombinant arylsulfatase a
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
BRPI0614852B1 (pt) 2005-08-24 2019-06-18 Boehringer Ingelheim International Gmbh Pulverizador
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
DK2007506T3 (da) * 2006-03-31 2014-06-16 Danisco Us Inc Tangentialstrømningsfiltreringsapparater, -systemer og -fremgangsmådertil separering af forbindelser
ES2294976B1 (es) 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
US10080853B2 (en) 2011-05-23 2018-09-25 Boehringer Ingelheim International Gmbh Nebulizer
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2012161685A1 (en) 2011-05-23 2012-11-29 Boehringer Ingelheim International Gmbh Nebulizer
JP2013043865A (ja) * 2011-08-25 2013-03-04 Osaka Prefecture Univ 血中脂質降下剤及び高分子アディポネクチン産生促進剤
GB201115874D0 (en) 2011-09-14 2011-10-26 Astrazeneca Ab Inhaler
GB201122430D0 (en) 2011-12-23 2012-02-08 Xstalbio Ltd Reconstitution method for high concentration dry protein formulation
CN104755489B (zh) * 2012-10-30 2019-01-15 弗·哈夫曼-拉罗切有限公司 使用双级切线流超滤纯化多肽

Also Published As

Publication number Publication date
CN118085011A (zh) 2024-05-28
AU2017313268A1 (en) 2019-02-07
CN110198952B9 (zh) 2024-05-28
US11572385B2 (en) 2023-02-07
CA3031860A1 (en) 2018-02-22
CN110198952B (zh) 2024-03-01
JP2024081786A (ja) 2024-06-18
JP2022120016A (ja) 2022-08-17
AU2017313268B2 (en) 2024-01-18
JP7114567B2 (ja) 2022-08-08
KR102457855B1 (ko) 2022-10-25
CN110198952A (zh) 2019-09-03
KR20190038921A (ko) 2019-04-09
JP2019535641A (ja) 2019-12-12
WO2018033482A1 (en) 2018-02-22
US20190309016A1 (en) 2019-10-10
EP3500588A1 (de) 2019-06-26
AU2024202299A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
SG11201901081XA (en) Process for the preparation of highly concentrated liquid formulations containing biomolecules
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201807912SA (en) Vaccine against rsv
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201907034PA (en) Methods of treating influenza
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201908280SA (en) "chimeric molecules and uses thereof"
SG11201811807XA (en) Dairy product and process
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201901684XA (en) Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use
SG11201902531QA (en) Liquid pharmaceutical composition
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201407988UA (en) Process for improved opioid synthesis
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201903417PA (en) Ringing gel composition
SG11201808964PA (en) Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201909048TA (en) Use of klk5 antagonists for treatment of a disease